Loading patent…
AssigneesBurnham Institute for Medical Research, The Regents of the University of California
InventorsDouglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen
Estimating the term…
The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
A peptide or peptidomimetic, having a length of less than 60 amino acid residues and comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKGAKAR (SEQ ID NO:19), FRVGVADV (SEQ ID NO:27), CEYQLDVE (SEQ ID NO:34) and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
A conjugate, comprising a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas, said peptide or peptidomimetic comprising at least 5 contiguous amino acids of the amino acid sequence CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof, or wherein said peptide or peptidomimetic binds specifically to a cognate receptor for SEQ ID NO:34.
11-22. (canceled)
A conjugate, comprising a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, said peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKGAKAR (SEQ ID NO:19) and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof, or wherein said peptide or peptidomimetic binds specifically to a cognate receptor for SEQ ID NO:19 or SEQ ID NO:35.
(canceled)
31-43. (canceled)
47-54. (canceled)
A conjugate, comprising a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to premalignant and malignant pancreatic vasculature, said peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from FRVGVADV (SEQ ID NO:27), or a conservative variant or peptidomimetic thereof, or wherein said peptide or peptidomimetic binds specifically to a cognate receptor for SEQ ID NO:27.
56-67. (canceled)
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides or peptidomimetics that selectively home to vasculature of premalignant pancreas, each of said peptides or peptidomimetics comprising at least 5 contiguous amino acids of the amino acid sequence CEYQLDVE (SEQ ID NO:34), or wherein each of said peptides or peptidomimetics binds specifically to a cognate receptor for SEQ ID NO:34;
76-93. (canceled)
Dependencies are inferred from the claim text.